Sign In
Buy IMCC
$0.289
-0.0057 (-1.93%)
At Close: Jun 03, 2026
IM Cannabis Provides Update on German Operations and Financial Outlook
08:40am, Friday, 23'rd Jul 2021
TORONTO, ON, BAD OLDESLOE, GERMANY, and GLIL YAM, ISRAEL / ACCESSWIRE / July 23, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC) (NASDAQ:IMCC), a multi-country operator ("MCO") in the med
IM Cannabis Provides Business, Legal and Regulatory Update
07:55am, Tuesday, 13'th Jul 2021
IMC subsidiary, Adjupharm, to expand German product portfolio with unique strains via supply agreements with The Green Organic Dutchman and Natural MedCo German Brand Institute awards IMC with the "Ge
Weed Companies On The Move: IM Cannabis Completes Purchase Of MYM Nutraceuticals
01:39pm, Friday, 09'th Jul 2021
Multi-country medical and recreational cannabis operator, IM Cannabis (CSE: IMCC) (NASDAQ: IMCC) confirmed Friday it has completed its previously announced acquisition of MYM Nutraceuticals (CSE
IM Cannabis Closes Acquisition of MYM Nutraceuticals
08:45am, Friday, 09'th Jul 2021
TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / July 9, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC)(CSE:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreat
MYM Shareholders Overwhelmingly Approve Plan of Arrangement with IM Cannabis
07:25am, Tuesday, 06'th Jul 2021
Highland Grow is currently profitable on an EBITDA basis, unlocks margin expansion and is expected to be immediately accretive to IM Cannabis Super premium positioning, complementary brands, enhanced
IM Cannabis Clinical Survey Reports Efficacy Of Its-Branded Stains For Conditions Such As PTSD, Insomnia, Back Pain, IBS
09:10am, Friday, 18'th Jun 2021
IM Cannabis Corp. (NASDAQ: IMCC) (CSE:IMCC) released promising results Thursday of a survey that evaluated the effectiveness of seven company-branded medical cannabis strains in treating seven hea
IM Cannabis Clinical Survey Confirms Effectiveness of Proprietary Strains in Alleviating Symptoms of Seven Key Health Conditions
09:05am, Thursday, 17'th Jun 2021
Conditions Evaluated Include Oncology, PTSD, Rheumatoid Arthritis, Chronic Pain, Insomnia, Back Pain and Inflammatory Bowel Diseases Conducted by Leading Contract Research Organization for Cannabis Re
IM Cannabis stock rallies toward an 8-day win streak after bullish analyst call
02:10pm, Thursday, 10'th Jun 2021
The U.S.-listed shares of IM Cannabis Corp. rallied 3.2% in afternoon trading Thursday, putting them on track for an eighth straight gain, after a bullish call from Alliance Global Partners analyst Aa
IM Cannabis, FLOWR Sign Multi-Year Deal To Import Medical Marijuana From Canada To Israel
02:54pm, Wednesday, 09'th Jun 2021
Israel-based multi-country operator IM Cannabis (CSE:IMCC) (NASDAQ:IMCC) announced it signed a three-year deal with Canadian licensed producer The FLOWR Corporation (OTC:FLWPF), under which the latter
IM Cannabis Gets Into Adult-Use Cannabis Market With Wagners Brand Launch In Canada
02:55pm, Monday, 07'th Jun 2021
Trichome JWC Acquisition (TJAC), the Canadian subsidiary of multi-country operator IM Cannabis (CSE:IMCC) (NASDAQ:IMCC), announced last week the launch of WAGNERS, a new adult-use cannabis brand in th
TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / June 7, 2021 / IM Cannabis Corp. (the "Company" or "IMC") (CSE:IMCC) (NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recrea
IM Cannabis Reports Record Q1 2021 Results
01:55pm, Monday, 17'th May 2021
Q1 2021 revenues of $8.8 million, an 80% sequential increase from Q4 2020 with Gross margin of 53% Strong sequential growth expected to continue with focus on further expanding premium product portfol
IM Cannabis Announces Proposed Public Offering of Securities
06:35pm, Tuesday, 04'th May 2021
TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / May 4, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC)(NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreat
With Israel 's Fast-Paced E-Commerce Adoption and Cannabis Market's High Growth Rate (Averaging 4 Percent 1 per Month), Panaxia's Online Platform to Support Patient Base Expansion Acquisition Broadens
IM Cannabis Reports Fiscal 2020 Results; Provides Preliminary Q1 Results and Q2 Outlook
08:55am, Friday, 23'rd Apr 2021
Q4 2020: revenues of $4.9 million and gross margin of 57%1; FY 2020: revenues of $15.9 million and gross margin of 55% 1 . Preliminary unaudited Q1 2021 revenues expected to be in the range of $8.5 -
